support@nanobiousa.com

1-888-678-8889 (USA)

3WJ – targeting ligand-antiMIR21
3WJ – targeting ligand-antiMIR21

Purpose:This nanoparticle can be used for specific delivery of anti-microRNA21 to cells in vitro and in vivo.

Get Quote
  Product Name Catalog number Synthesis scale
 
Triple Negative Breast Cancer (TNBC)
 
 
 
 
3WJ – RFA (TNBC)-antiMIR21 RNP-M21-01-1
1 nmol
RNP-M21-01-2
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Triple Negative Breast Cancer (TNBC) cells and antiMIR21]

3WJ – RFM-antiMIR21    RNP-M21-07-1 1 nmol
RNP-M21-07-2  50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a mutant aptamer (serving as a targeting control) and antiMIR21]

3WJ – RFA(TNBC)-Scr   RNP-MSc-01-1
1 nmol
RNP-MSc-01-2  
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Triple Negative Breast Cancer (TNBC) cells and scramble miRNA ]

 
HER2+ 
Cancer
 
 
 
3WJ – RFA (HER2)-antiMIR21 RNP-M21-03-1
1 nmol
RNP-M21-03-2 
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting HER2 + cancer cells and antiMIR21]

3WJ – RFM-antiMIR21 RNP-M21-07-1 1 nmol
RNP-M21-07-2  50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a mutant RNA aptamer (serving asa targeting control) and antiMIR21]

3WJ – RFA(HER2)-Scr   RNP-MSc-03-1
1 nmol
RNP-MSc-03-2 
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting HER2 + cancer cells and scramble miRNA ]

 
Folate Receptor+ Cancer 
 
 
 
 
 
3WJ – RFC (FA)-antiMIR21 RNP-M21-05-1
1 nmol
RNP-M21-05-2
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a folate ligand for targeting folate receptor (+) cells and antiMIR21]

3WJ – RF-antiMIR21  RNP-M19-08-1 1 nmol
RNP-M19-08-2 50 nmol

[Description: Serum stable 3WJ RNA nanoparticle without ligand (serving as vector control) but with antiMIR21]

3WJ – RFC(FA)-Scr RNP-MSc-05-1
1 nmol
RNP-MSc-05-2 
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a folate ligand for targeting folate receptor (+) cells and scramble miRNA]

 
Epithelial
Cancer 
 
 
 
 
 
 
3WJ – RFA (EC)-antiMR21 RNP-M21-04-1
1 nmol
RNP-M21-04-2 
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Epithelial Cancer (EC) cells and antiMIR21]

3WJ – RFM-antiMIR21    RNP-M19-07-1 1 nmol
RNP-M19-07-2 50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a mutant aptamer (serving as a targeting control) and antiMIR21]

3WJ – RFA(EC)-Scr  RNP-MSc-04-1
1 nmol
RNP-MSc-04-2
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Epithelial Cancer (EC) cells and scramble miRNA]

 
Galactose Receptor+
Cancer 
 
 
 
 
 
3WJ – RFC (GL)-antiMIR21 RNP-M21-06-1
1 nmol
RNP-M21-06-2 
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a galactose ligand for targeting liver cancer cells and antiMIR21]

3WJ – RF-antiMIR21     RNP-M21-08-1 1 nmol
RNP-M21-08-2 50 nmol

Description: Serum stable 3WJ RNA nanoparticle without ligand (serving as vector control) but with antiMIR21]

3WJ – RFC(GL)-Scr   RNP-MSc-06-1
1 nmol
RNP-MSc-06-2 
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a galactose ligand for targeting liver cancer cells and scramble miRNA]

 
PSMA+
Cancer 
 
 
 
 
 
3WJ – RFA (PC)-antiMR21 RNP-M21-02-1
1 nmol
RNP-M21-02-2
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Prostate Cancer (PC) cells and antiMIR21]

3WJ – RFM-antiMIR21    RNP-M19-07-1 1 nmol
RNP-M19-07-2 50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a mutant aptamer (serving as a targeting control) and antiMIR21]

3WJ – RFA(PC)-Scr   RNP-MSc-02-1
1 nmol
RNP-MSc-02-2
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Prostate Cancer (PC) cells and scramble miRNA]


Copyright © Nanobio Delivery Pharmaceutical Co., Ltd. All rights reserved.